New strategies for Alzheimer's disease and cognitive impairment.
Approximately five million people suffer with Alzheimer's disease (AD) and more than twenty-four million people are diagnosed with AD, pre-senile dementia, and other disorders of cognitive loss worldwide. Furthermore, the annual cost per patient with AD can approach $200,000 with an annual population aggregate cost of $100 billion. Yet, complete therapeutic prevention or reversal of neurovascular injury during AD and cognitive loss is not achievable despite the current understanding of the cellular pathways that modulate nervous system injury during these disorders. As a result, identification of novel therapeutic targets for the treatment of neurovascular injury would be extremely beneficial to reduce or eliminate disability from diseases that lead to cognitive loss or impairment. Here we describe the capacity of intrinsic cellular mechanisms for the novel pathways of erythropoietin and forkhead transcription factors that may offer not only new strategies for disorders such as AD and cognitive loss, but also function as biomarkers for disease onset and progression.
Maiese
Kenneth
K
Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, USA. kmaiese@med.wayne.edu
Chong
Zhao Zhong
ZZ
Hou
Jinling
J
Shang
Yan Chen
YC
D000544:Alzheimer Disease / Q000378:metabolism / Q000628:therapy*; D003072:Cognition Disorders / Q000378:metabolism / Q000628:therapy*; D004921:Erythropoietin / Q000378:metabolism; D051858:Forkhead Transcription Factors / Q000378:metabolism; D006801:Humans; D009420:Nervous System / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism
D051858:Forkhead Transcription Factors; D017382:Reactive Oxygen Species; D004921:Erythropoietin